News Scan for Aug 21, 2018

News brief

HPV testing affirmed as effective tool to screen for cervical cancer

The value of human papillomavirus (HPV) testing as an additional tool to screen for cervical cancer—joining the traditional Pap smear—has been affirmed by a new meta-analysis and an expert panel’s recommendation based on that analysis, as explained in a set of articles today in the Journal of the American Medical Association (JAMA).

The US Preventive Services Task Force (USPSTF) used the meta-analysis results in revising its recommendation on cervical cancer screening to include a larger role for testing for high-risk HPV strains. HPV causes about 90% of cervical cancer cases.

The task force’s new “A” recommendation for women ages 30 to 65 years lists primary high-risk HPV testing alone as an option, along with the previous recommendation of either high-risk HPV and Pap smear (cytology) together (“cotesting”) every 5 years or continued cytology every 3 years. Cytology every 3 years remains the recommended way to screen women 21 to 29 years old.

The meta-analysis, led by Joy Melnikow, MD, MPH, of the University of California, Davis, included eight randomized controlled trials, five cohort studies, and one individual-participant-data meta-analysis.

The researchers found that high-risk HPV testing alone led to a significant increase in detection of severely abnormal cervical cells (CIN [cervical intraepithelial neoplasia] 3+), compared with cytology alone, in the first round of screening. Co-testing did not yield a significant increase in detection of CIN3+, compared with cytology alone.

The analysis also indicated, however, that both HPV alone and co-testing produced more false-positive results and higher follow-up colposcopy rates than cytology alone, “which could lead to more treatments with potential harms,” the report states.

"We found that regular screening with any method will lead to lower cervical cancer rates," Melnikow said in a UC-Davis press release. "In the US, where most women are not part of an organized screening program, our biggest challenge is reaching women who have not been screened."
Aug 21 JAMA articles: meta-analysis, USPSTF statement, related commentary
Aug 21 UC-Davis press release

 

H7N9 avian flu viruses brought into Japan via illegal raw poultry

Raw poultry brought illegally into Japan by airline passengers contained highly pathogenic and low-pathogenic H7N9 avian flu viruses, according to a study published yesterday in Virology.

This is the first report detailing the isolation of H7N9 from raw meat products outside mainland China and suggests that the illegal transport of poultry is a possible cause of the spread of the virus in Asia, the authors wrote.

The researchers tested confiscated poultry meat from travelers coming to Japan from May 2016 to January 2018. Dogs at customs stations detected the poultry, which included ducks, quail, and chickens. A total of 162 specimens were collected.

Three H7N9 and three H9N2 subtypes were isolated from meat- and organ-pooled samples of chicken (Gallus gallus) or Muscovy duck (Cairina moschata) meat products brought by passengers from China and Vietnam, the authors found.

H7N9 avian influenza viruses were first detected in China in 2013, and have since become a global threat. Though infrequently transmitted to humans, the virus can be deadly to people who come into close contact with infected birds and have caused at least 1,625 human cases and 623 deaths since 2013, according to statistics from the United Nations Food and Agriculture Organization.

"To prevent passengers carrying infectious [avian flu viruses] via contaminated products, it is important to increase publicity and awareness to ensure that passengers, particularly from areas where the virus is prevalent, comply with import regulations," the authors concluded.
Aug 20 Virology study

Stewardship / Resistance Scan for Aug 21, 2018

News brief

Study supports oral antibiotic monotherapy for most kids with UTIs

A study today in Pediatrics suggests that a dose of parenteral antibiotics prior to discharge from the emergency department (ED) is likely not necessary for most young children with urinary tract infections (UTIs).

In the study, researchers conducted a retrospective analysis of administrative data from 26 hospitals from 2010 through 2016 to better understand the value of a single dose of parenteral antibiotics in children with UTIs who are well enough to be discharged from the ED. While oral antibiotics are as effective as parenteral antibiotics in the treatment of UTIs in young children, and the American Academy of Pediatrics UTI guidelines recommend oral antibiotics alone for children with UTIs who are able to tolerate oral intake and are not ill-appearing, the administration of parenteral antibiotics before ED discharge remains a common practice.

The primary outcome of the study was an ED revisit within 3 days requiring admission. All ED revisits served as a secondary outcome.

Overall, 29,919 children with a median age of 8.6 months were included in the analysis; 36% (10,849) of those children received parenteral antibiotics before ED discharge, 4.0% (1,199) had a 3-day ED revisit, and 1.1% (336) had a 3-day revisit with admission. After adjusting for demographic factors, clinical severity, and hospital-level factors, the researchers found that ED revisit rates with admission were similar among patients who received parenteral antibiotics and those who did not (1.3% vs. 1.0%; risk difference, 0.3%). Overall ED revisit rates were higher among patients who received parenteral antibiotics (4.8% vs. 3.3%; risk difference, 1.5%).

The authors of the study say the findings support the goal of using oral antibiotics as monotherapy for most children who are discharged with UTIs.
Aug 21 Pediatrics study

 

Researchers develop method for real-time surveillance of drug-resistant TB

A study today in PLoS Medicine by US and South African researchers describes a method to monitor drug-resistant tuberculosis (TB) by identifying high-burden communities using routinely collected laboratory data.

South Africa has one of the highest TB incidence rates globally (781 per 100,000 inhabitants), yet little is known about the spatial heterogeneity of TB or drug-resistant TB within the country. This kind of spatial information is required to understand where drug-resistant TB exists, to determine why it persists in those communities, and to create appropriate control and elimination strategies.  

To derive spatial estimates of drug-resistant TB in the country, the researchers retrospectively identified cases of TB and rifampicin-resistant TB (RR-TB) from all biological samples submitted for testing to the Western Cape National Health Laboratory Services (NHLS) from 2008 through June 2013. Because the NHLS database lacks unique patient identifiers, the researchers created a person-matching algorithm to match specimen records to individual patients. Cases were then aggregated by clinic location to estimate the percentage of RR-TB cases per clinic.

Of the 799,779 individuals who were mappable to clinic locations, 27.8% (222,735) had microbiologically confirmed TB, and, of these, 4.6% (10,255) had RR-TB. Mapping of cases at the clinic level showed that while the median percentage of RR-TB diagnosed at clinics was 4.3%, the percentage of diagnosed RR-TB cases ranged from 0% to 25% across Western Cape province, with significant yearly fluctuations in RR-TB percentages at several locations.

"Maps such as the ones we have created can be the platform for this next generation of disease surveillance," the authors of the study conclude. "Improved knowledge of subnational geographic variability of RR-tuberculosis is essential for the improved design and implementation of national and local responses to reduce drug-resistant tuberculosis transmission and for timely context-specific resource allocation."
Aug 21 PLoS Med study

This week's top reads